ConcertAI is sponsoring the Engaging Research to Achieve Cancer Care Equity (ERACE) Research Award. This award will provide early-stage career research investigators with monetary support and access to one of the most comprehensive cancer patient datasets available for research purposes in the United States.
The award is intended to support research aimed at examining potential differences in treatment patterns, outcomes, clinical practice, genomics, safety, and other issues related to cancer care among populations with existing disparities, particularly those that exist among racial and ethnic groups, which could inform strategies to eliminate cancer health disparities. The award will be granted based on individual merit and the candidate’s potential for long term impact in cancer disparity research.
APPLICANT ELIGIBILITY CRITERIA
Please download the Request for Applications (RFA) for eligibility criteria. Note that this is only for early-stage career research investigators.
Applicants who are uncertain about their eligibility are encouraged to contact firstname.lastname@example.org before starting an application.
This application requires a Letter of Intent (LOI). The LOI and full application must be submitted in accordance with the requirements and instructions of the ERACE LOI and Request for Applications (RFA) by the application deadline. All application materials must be in English and must be submitted through the Application Portal. Paper applications or applications sent by e-mail or fax will not be accepted. If you have questions, please email email@example.com.
- Letter of Intent Due: January 15, 2021, 11:59 PM ET
- Anticipated Letter of Intent Notification: February 12, 2021, 11:59 PM ET
- Full Application Due*: April 30, 2021, 11:59 PM ET
- Anticipated Notification of Award: May 14, 2021
Grants will be distributed following execution of signed Letter of Agreement
- Length of Proposed Project: 12 months
*Only applicants who have received approval for their LOI will be eligible to submit a full application.